M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy

• Published in: Journal of molecular neuroscience Vol. 20; no. 3; pp. 349 - 356
• Main Authors: Fisher, Abraham, Pittel, Zipora, Haring, Rachel, Bar-Ner, Nira, Kliger-Spatz, Michal, Natan, Niva, Egozi, Inbal, Sonego, Hagar, Marcovitch, Itzhak, Brandeis, Rachel
• Format: Journal Article
• Language: English
• Published: United States 2003
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Alzheimer Disease - physiopathology; Amyloid beta-Peptides - antagonists & inhibitors; Amyloid beta-Peptides - biosynthesis; Amyloid beta-Protein Precursor - cerebrospinal fluid; Amyloid beta-Protein Precursor - drug effects; Animals; Brain - drug effects; Brain - metabolism; Brain - physiopathology; Cell Death - drug effects; Cell Death - physiology; Disease Models, Animal; Down-Regulation - drug effects; Down-Regulation - physiology; Humans; Memory Disorders - drug therapy; Mice; Muscarinic Agonists - pharmacology; Oxidative Stress - drug effects; Oxidative Stress - physiology; Piperidines - pharmacology; Quinuclidines - pharmacology; Receptor, Muscarinic M1 - drug effects; Receptor, Muscarinic M1 - metabolism; Spiro Compounds - pharmacology; tau Proteins - drug effects; tau Proteins - metabolism; Thiazoles - pharmacology; Thiophenes

M1 muscarinic receptors (M1 mAChRs) play a role in an apparent linkage of three major hallmarks of Alzheimer's disease (AD): beta-amyloid (Abeta) peptide; tau hyperphosphorylation and paired helical filaments (PHFs); and loss of cholinergic function conducive to cognitive impairments. We evalua...